pypd-20260630
2026-06-30 --12-31 0001611842 false Q2 0001611842 2026-01-01 2026-06-30 0001611842 us-gaap:SubsequentEventMember 2026-07-17 2026-07-17 0001611842 us-gaap:SubsequentEventMember pypd:NewDrugApplicationMember 2026-07-17 2026-07-17 0001611842 pypd:August2024Member srt:ScenarioForecastMember 2026-08-01 2026-08-31 0001611842 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2026-07-01 2026-07-31 0001611842 us-gaap:SubsequentEventMember srt:MaximumMember 2026-07-01 2026-07-31 0001611842 us-gaap:SubsequentEventMember srt:MinimumMember 2026-07-01 2026-07-31 0001611842 srt:ScenarioForecastMember 2026-08-01 2026-08-31 0001611842 us-gaap:SubsequentEventMember 2026-07-01 2026-07-31 0001611842 2025-01-01 2025-06-30 0001611842 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001611842 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001611842 us-gaap:StockOptionMember 2025-01-01 2025-06-30 0001611842 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001611842 2026-06-30 0001611842 pypd:June2025Member 2026-01-01 2026-06-30 0001611842 pypd:June2025Member 2026-06-30 0001611842 pypd:August2024Member 2026-01-01 2026-06-30 0001611842 pypd:August2024Member 2026-06-30 0001611842 pypd:April2022OneMember 2026-01-01 2026-06-30 0001611842 pypd:April2022OneMember 2026-06-30 0001611842 pypd:July2022Member 2026-01-01 2026-06-30 0001611842 pypd:July2022Member 2026-06-30 0001611842 pypd:April2022Member 2026-01-01 2026-06-30 0001611842 pypd:April2022Member 2026-06-30 0001611842 pypd:GeneralAndAdministrativeMember 2025-01-01 2025-06-30 0001611842 pypd:GeneralAndAdministrativeMember 2026-01-01 2026-06-30 0001611842 pypd:MarketingAndBusinessDevelopmentMember 2025-01-01 2025-06-30 0001611842 pypd:MarketingAndBusinessDevelopmentMember 2026-01-01 2026-06-30 0001611842 pypd:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-06-30 0001611842 pypd:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-06-30 0001611842 pypd:EmployeesAndNonEmployeesMember 2026-01-01 2026-06-30 0001611842 pypd:EmployeesAndNonEmployeesMember 2026-06-30 0001611842 pypd:EmployeesAndNonEmployeesMember 2025-12-31 2025-12-31 0001611842 pypd:EmployeesAndNonEmployeesMember 2025-12-31 0001611842 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0001611842 pypd:OfficersMember 2026-01-01 2026-06-30 0001611842 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001611842 us-gaap:WarrantMember 2026-03-06 2026-03-06 0001611842 us-gaap:WarrantMember 2026-01-08 2026-01-08 0001611842 us-gaap:CommonStockMember 2026-01-08 0001611842 pypd:NewWarrantsMember 2026-01-08 0001611842 srt:MinimumMember us-gaap:CommonStockMember us-gaap:WarrantMember 2026-06-30 0001611842 srt:MaximumMember us-gaap:CommonStockMember us-gaap:WarrantMember 2026-06-30 0001611842 us-gaap:CommonStockMember pypd:AbeyanceMember 2025-12-01 2025-12-31 0001611842 pypd:AbeyanceMember 2025-12-01 2025-12-31 0001611842 us-gaap:IPOMember 2025-06-16 2025-06-16 0001611842 pypd:NewWarrantsSharesMember 2025-06-16 0001611842 us-gaap:CommonStockMember pypd:NewWarrantsSharesMember 2025-06-16 0001611842 srt:MinimumMember pypd:NewWarrantsMember 2025-06-16 0001611842 2025-06-16 0001611842 us-gaap:CommonStockMember pypd:January2024WarrantsMember 2025-06-16 0001611842 pypd:December2024WarrantsMember 2025-06-16 0001611842 pypd:InducementLetterMember us-gaap:CommonStockMember pypd:January2024WarrantsMember 2025-06-16 0001611842 pypd:InducementLetterMember pypd:January2024WarrantsMember 2025-06-16 0001611842 us-gaap:CommonStockMember 2025-09-04 0001611842 us-gaap:CommonStockMember 2025-06-09 0001611842 pypd:PreFundedWarrantsMember 2025-09-04 0001611842 pypd:PreFundedWarrantsMember 2025-06-09 0001611842 us-gaap:WarrantMember 2025-06-23 0001611842 srt:MaximumMember us-gaap:WarrantMember 2025-06-16 0001611842 us-gaap:PrivatePlacementMember 2024-12-26 2024-12-26 0001611842 2024-12-26 2024-12-26 0001611842 us-gaap:CommonStockMember pypd:December2024WarrantsMember 2024-12-26 2024-12-26 0001611842 us-gaap:WarrantMember 2024-12-26 0001611842 us-gaap:WarrantMember 2024-12-26 2024-12-26 0001611842 2024-12-26 0001611842 us-gaap:CommonStockMember 2026-06-30 0001611842 pypd:PreFundedWarrantsMember 2026-06-30 0001611842 pypd:August2024WarrantsMember 2026-01-01 2026-06-30 0001611842 us-gaap:CommonStockMember pypd:August2024WarrantsMember 2026-06-30 0001611842 pypd:August2024WarrantsMember 2026-06-30 0001611842 us-gaap:CommonStockMember 2025-06-30 0001611842 pypd:PreFundedWarrantsMember 2025-06-30 0001611842 us-gaap:PrivatePlacementMember 2024-08-01 2024-08-01 0001611842 2024-08-01 2024-08-01 0001611842 us-gaap:CommonStockMember pypd:August2024WarrantsMember 2024-08-01 0001611842 us-gaap:CommonStockMember pypd:August2024WarrantsMember 2024-08-01 2024-08-01 0001611842 us-gaap:WarrantMember 2024-08-01 0001611842 us-gaap:WarrantMember 2024-08-01 2024-08-01 0001611842 us-gaap:CommonStockMember 2024-08-01 0001611842 us-gaap:CommonStockMember 2024-08-01 2024-08-01 0001611842 pypd:January2024WarrantsMember 2026-01-31 0001611842 pypd:January2024WarrantsMember 2025-06-16 0001611842 us-gaap:CommonStockMember us-gaap:WarrantMember 2025-05-20 0001611842 us-gaap:WarrantMember 2025-05-20 0001611842 us-gaap:WarrantMember 2024-01-04 2024-01-04 0001611842 2024-01-04 2024-01-04 0001611842 pypd:DefinitiveSecuritiesPurchaseAgreementMember 2024-01-04 0001611842 us-gaap:PrivatePlacementMember pypd:January2024WarrantsMember 2024-01-04 0001611842 pypd:DefinitiveSecuritiesPurchaseAgreementMember pypd:January2024WarrantsMember 2024-01-04 0001611842 pypd:DefinitiveSecuritiesPurchaseAgreementMember pypd:PreFundedWarrantsMember 2024-01-04 0001611842 pypd:DefinitiveSecuritiesPurchaseAgreementMember 2024-01-04 2024-01-04 0001611842 2025-11-26 0001611842 2025-12-31 0001611842 pypd:IsraelInnovationAuthorityOfTheMinistryOfEconomyMember pypd:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-06-30 0001611842 2025-06-01 2025-06-30 0001611842 2025-06-30 0001611842 2024-12-31 0001611842 us-gaap:RetainedEarningsMember 2025-06-30 0001611842 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001611842 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001611842 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001611842 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001611842 us-gaap:RetainedEarningsMember 2024-12-31 0001611842 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001611842 us-gaap:CommonStockMember 2024-12-31 0001611842 us-gaap:RetainedEarningsMember 2026-06-30 0001611842 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001611842 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001611842 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001611842 us-gaap:RetainedEarningsMember 2025-12-31 0001611842 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001611842 us-gaap:CommonStockMember 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of: August 2026 (Report No. 2)

 

Commission File Number: 001-38428

 

PolyPid Ltd.

(Translation of registrant’s name into English)

 

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

 Form 20-F       Form 40-F

 

 

 

 

 

 

CONTENTS

 

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) consists of PolyPid Ltd.’s (the “Company”): (i) Interim Condensed Consolidated Financial Statements as of June 30, 2026, which is attached hereto as Exhibit 99.1; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2026, which is attached hereto as Exhibit 99.2.

 

The contents of this Form 6-K are incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034)  and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703, File No. 333-280662, File No. 333-289570 and File No. 333-298261) filed  with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   PolyPid Ltd.’s Interim Condensed Financial Statements as of June 30, 2026.
99.2   PolyPid Ltd.’s Management’s Discussion and Analysis of Financial Condition and Results of Operation for the Six Months Ended June 30, 2026.
101   The following financial information from the Registrant’s Interim Condensed Financial Statements as of June 30, 2026, formatted in XBRL (eXtensible Business Reporting Language): (i) Interim Condensed Consolidated Balance Sheets, (ii) Interim Condensed Consolidated Statements of Operations, (iii) Interim Condensed Consolidated Statements of Shareholders’ Equity; (iv) Interim Condensed Consolidated Statements of Cash Flows, and (v) Notes to Interim Condensed Consolidated Financial Statements.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  POLYPID LTD.
     
Date: August 12, 2026 By: /s/ Dikla Czaczkes Akselbrad
    Name: Dikla Czaczkes Akselbrad
    Title: Chief Executive Officer

 

3